How Big Is Germany's Medical Cannabis Market?

Germany's medical market is big because of one regulatory change. Jamie Pearson, president of New Holland Group, points to Germany taking cannabis off the narcotics list as the mechanism behind the growth. After that, any doctor could prescribe it like a normal medication, and state health insurance or private insurance pays for it. In his words from February 2025, "cannabis is a non-narcotic in Germany, and the medical program has predictably exploded." That is not marketing language. It is what happens when you remove doctor gatekeeping and out of pocket cost at the same time.

The market is already real money

Organigram CEO James Yamanaka gives the most recent numbers, in Germany Is the Engine, published in June 2026. He put the market at about €2.5 billion, driven by roughly 800,000 patients out of a population of 83 to 84 million, and said that from the trends he was seeing it should be around €4.8 billion in two years. Even that, he noted, would mean only about 1.8 million patients. He also said Sanity Group's revenues and profits grew 100%.

The gap between those numbers and the country's size is the opportunity. Back in March 2024, before Germany's April 2024 law change took effect, equity analyst Pablo Zuanic put the program at roughly 0.2% of the population, against 3.5% in Florida and 4% in Pennsylvania, and said going to 4% would mean a market 20 times bigger (his episode). Yamanaka's 2026 patient count, about 800,000, is already roughly 1% of the population. Some of that gap has closed. Most of it has not.

Supply is a Canadian story

Here is the part US operators miss. In mid 2026 Yamanaka said about 46% of the German market is supplied by Canadian companies because US companies can't do it, and that probably 60% of the European industry is Canadian flower. Germany has opened its own cultivation: Pearson explains that the original medical law allowed only four companies to grow a limited amount in country, and the new law lifted that restriction, so anybody can grow in Germany as long as it is EU-GMP certified pharmaceutical grade cannabis. That is a high bar, and Pearson says much US grown product would not pass it.

What this means for operators

If you are a US operator watching Germany, direct export is not available to you under current federal law. The access point runs through Canada, through supply relationships or ownership there, and through EU-GMP standards that most US facilities were never built to. Zuanic named Tilray, Aurora and Kiff as big participants as of early 2024, with Curaleaf the only MSO exporting from Canada into Germany under its own brands. The companies that did the compliance work early are the ones selling into a market that was still growing fast as of mid 2026.